Oncosil Medical Ltd Asset Resilience Ratio
Oncosil Medical Ltd asset resilience ratio. Oncosil Medical Ltd (OSL) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Oncosil Medical Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Oncosil Medical Ltd (2011–2025)
Asset resilience ratio of Oncosil Medical Ltd from 2011 to 2025. This chart shows how Oncosil Medical Ltd's Asset Resilience Ratio has changed over time. Read OSL current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Oncosil Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Oncosil Medical Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Oncosil Medical Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Oncosil Medical Ltd Industry Peers by Asset Resilience Ratio
Compare Oncosil Medical Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Ningbo David Medical Device Co Ltd
SHE:300314 |
Medical Devices | 5.11% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 15.99% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Nova EYE Medical Ltd
AU:EYE |
Medical Devices | 11.08% |
|
Promimic AB
ST:PRO |
Medical Devices | 8.62% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Oncosil Medical Ltd Asset Resilience Ratio by Year (2011–2025)
Oncosil Medical Ltd asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Oncosil Medical Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$7.15 Million ≈ $5.06 Million |
-- |
| 2024-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$6.72 Million ≈ $4.75 Million |
-- |
| 2023-06-30 | 1.02% | AU$116.57K ≈ $82.48K |
AU$11.47 Million ≈ $8.12 Million |
+0.33pp |
| 2022-06-30 | 0.68% | AU$89.27K ≈ $63.16K |
AU$13.07 Million ≈ $9.25 Million |
+0.04pp |
| 2021-06-30 | 0.64% | AU$90.53K ≈ $64.06K |
AU$14.15 Million ≈ $10.01 Million |
+0.35pp |
| 2020-06-30 | 0.29% | AU$69.21K ≈ $48.97K |
AU$24.06 Million ≈ $17.02 Million |
-66.20pp |
| 2019-06-30 | 66.49% | AU$7.76 Million ≈ $5.49 Million |
AU$11.67 Million ≈ $8.26 Million |
-9.98pp |
| 2018-06-30 | 76.48% | AU$15.21 Million ≈ $10.76 Million |
AU$19.88 Million ≈ $14.07 Million |
+8.70pp |
| 2017-06-30 | 67.77% | AU$8.00 Million ≈ $5.66 Million |
AU$11.80 Million ≈ $8.35 Million |
+47.27pp |
| 2016-06-30 | 20.50% | AU$3.26 Million ≈ $2.31 Million |
AU$15.90 Million ≈ $11.25 Million |
-28.07pp |
| 2015-06-30 | 48.57% | AU$3.60 Million ≈ $2.55 Million |
AU$7.41 Million ≈ $5.24 Million |
+3.43pp |
| 2014-06-30 | 45.14% | AU$4.35 Million ≈ $3.08 Million |
AU$9.64 Million ≈ $6.82 Million |
+44.22pp |
| 2013-06-30 | 0.92% | AU$57.35K ≈ $40.58K |
AU$6.24 Million ≈ $4.42 Million |
-2.24pp |
| 2012-06-30 | 3.16% | AU$79.75K ≈ $56.43K |
AU$2.52 Million ≈ $1.79 Million |
-1.50pp |
| 2011-06-30 | 4.66% | AU$141.18K ≈ $99.89K |
AU$3.03 Million ≈ $2.14 Million |
-- |
About Oncosil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorp… Read more